Baseline Blood Indices and Prolonged Length of Hospital Stay

Baseline Blood Indices as a Marker for Prolonged Length of Hospital Stay in Diabetic Older Patients With Mild or Moderate Covid-19 Infection

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05054283

Enrollment

Registered

2021-09-23

Start date

2021-10-01

Completion date

2021-12-01

Last updated

2021-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pneumonia, Diabetes Mellitus, Type 2, Hospitalism

Keywords

Length of hospital stay, Covid-19 Pneumonia, Diabetes Mellitus

Brief summary

During a pandemic, length of hospital stay (LOS) is critical to managing high patient volumes and preserves access to care related to non-COVID-19 for maintaining the healthcare system. Moreover, identiﬁcation of prolonged hospital stay may allow physicians to reevaluate critical patients, focused delivery of specific interventions, and improve the efficiency of hospital care. Furthermore, in previous recent studies, attention has been paid to patients with diabetes and COVID-19 infection may require a prolonged LOS. However, there is little evidence on prognostic factors associated with an extension of hospitalization in mild or moderate illness due to COVID-19 infection. Therefore, it is crucial to determine the most vulnerable patients with diabetes mellitus even if they have a non-severe COVID-19 infection during the pandemic. We hypothesize that the clinically relevant inflammatory parameters may have an impact on LOS in older adults with diabetes and non-severe COVID-19 infection. Therefore, we aim to investigate whether baseline inflammatory parameters on admission hospitals as possible predictors of prolonged LOS in older adults with diabetes and non-severe COVID-19 infection during the pandemic.

Interventions

DIAGNOSTIC_TESTInflamatory biomarkers

laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* We included all hospitalized Covid-19 patients with diabetes mellitus according to the any established diagnosis prior to admission or American Diabetes Association guidelines for diagnostic criteria

Exclusion criteria

* The patients with severe Covid-19 infection, secondary diabetes or type 1 diabetes mellitus were excluded.

Design outcomes

Primary

Measure	Time frame	Description
Prolonged Length of hospital	at least 2 week	The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization.

Countries

Turkey (Türkiye)

Contacts

Primary ContactBilal KATIPOGLU, MD

drbilal07@gmail.com5543330380

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026